<DOC>
	<DOCNO>NCT01730690</DOCNO>
	<brief_summary>Major change epidemiological characteristic bacterial meningitis observe result change behaviour , human intervention ( use antibiotic , prophylactic vaccination ) , well poorly elucidate mechanism responsible epidemic outbreak . The objective study identify determinant in-hospital mortality bacterial meningitis adult . Hypothesis : standardize data collection concern case bacterial meningitis adult telephone follow-up would allow analysis determinant mortality neurosensory sequela , description psychosocial impact proposal new treatment strategy .</brief_summary>
	<brief_title>Bacterial Meningitis Adults : Analysis Determinants Mortality Neurosensory Sequelae</brief_title>
	<detailed_description>Introduction : Bacterial meningitis rare ( 1,200 case per year France , 50 % occur adult ) serious disease ( 20 % mortality acute phase ; neurosensory sequelae 30 % survivor ) . Major change epidemiological characteristic bacterial meningitis observe result change behaviour , human intervention ( use antibiotic , prophylactic vaccination ) , well poorly elucidate mechanism responsible epidemic outbreak . No standardized clinical , microbiological prognostic data collection concern bacterial meningitis adult available France . Hypothesis : Standardized data collection concern case bacterial meningitis adult telephone follow-up would allow analysis determinant mortality neurosensory sequela , description psychosocial impact proposal new treatment strategy . Primary objective : To identify determinant in-hospital mortality bacterial meningitis adult . Secondary objective : To describe epidemiological characteristic community-acquired bacterial meningitis adult , change characteristics relation vaccine status affect adult his/her family ; characterize clinical microbiological failure determinant ( pharmacological , microbiological , immunological , etc . ) ; analyse determinant neurosensory sequelae failure return work 1 month , 6 month 12 month . Primary endpoint : In-hospital mortality ( D30 ) . Secondary endpoint : History include vaccination case family , clinical , microbiological ( specie , susceptibility , virulence factor , cerebrospinal fluid CSF ) culture D0 H48 ) , image characteristic ; treatment , CSF antibiotic concentration , neurological sequela ( modified Rankin , Glasgow Outcome Scale , IQCODE ) M1 , M6 M12 , quality life test SF12 , WHO QoL , CESD ) M1 , M6 , M12 , hear loss ( audiometric test , hereditary hearing impairment ( HHI ) , telephone speech test noise ) M1 , M6 , M12 . Methodology , study design : National observational cohort study comprehensive recruitment participate centre . Legal classification project : Epidemiological study . Number subject require : The inclusion 150 case meningitis per year would allow collection 450 case period 3 year . For mortality rate 20 % , would able estimate percentage confidence interval Â± 3.7 % ( 95 % confidence interval : 16.3-23.7 ) . With 90 death , power 80 % level significance 5 % ( two-tailed ) , sample size would demonstrate relative risk 1.8 prevalence risk factor 25 % 2.6 prevalence risk factor 10 % . Inclusion criterion : Adult community-acquired bacterial meningitis define presence least one follow criterion : 1/ Positive CSF culture and/or positive soluble antigen CSF without cell reaction ; 2/ Positive PCR CSF ; 3/ Purpura fulminant ( without positive CSF culture ) ; Positive polymerase chain reaction ( PCR ) blood and/or positive blood culture AND CSF cell reaction . Non inclusion criterion : Age le 18 year old refusal participate . Inclusion period : 3 year . Duration participation one patient : 12 month . Number participate center : Constitution participate center dual investigator team comprise clinician ( infectious disease physician , intensive care physician , neurologist ) microbiologist ( participate national network `` OBSERVATOIRES REGIONAUX DU PNEUMOCOQUE '' [ Regional Pneumococcal Observatories ] ) . Declaration microbiologist data management centre . On-site validation case dual investigator team national multidisciplinary validation unit . Mean number inclusion per month per centre : 0.5</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Bacterial</mesh_term>
	<criteria>Positive CSF culture and/or positive soluble antigen CSF without cell reaction Positive PCR CSF Purpura fulminant ( without positive CSF culture ) Positive PCR blood and/or positive blood culture AND CSF cell reaction . Age le 18 year old Refusal participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Bacterial meningitis adult</keyword>
	<keyword>determinant in-hospital mortality</keyword>
</DOC>